The Lessons of Asilomar for Today’s Science
By Alexander Capron,
The New York Times
| 05. 28. 2015
Untitled Document
There is a precedent for establishing internationally agreed-upon limits for new science, though it can be hard to do.
In 1973, scientists who were using novel molecular techniques to splice DNA between different organisms asked the National Academy of Sciences to consider the potential hazards as they might affect the public. In July 1974, an Academy-appointed committee publicly called for a large category of experiments to be suspended until leaders in the field could plan a way forward. Such a self-imposed moratorium on basic research was unprecedented, but it worked.
A hundred and fifty scientists and physicians from around the world gathered in February 1975 at the Asilomar conference center near Monterey, California, in what one scientist termed an amazing show of “self denial and social responsibility in the face of strong intellectual temptation” to continue the experiments.
The outcome of the meeting was equally impressive. Categories of experiments were graded by their riskiness: Some were deemed excessively dangerous and kept off-limits, while others were to be allowed once the appropriate biological and physical means of risk-containment had...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...